MUC16 and ovarian carcinoma: Moreover, Ad5/3–Δ24 was tested in a phase I clinical trial against recurrent ovarian cancer, where it was demonstrated that almost 30% of women had a decrease in CA-125 (cancer antigen 125) levels at one month, while the adverse events, such as fever, myalgia, fatigue, and nausea were also moderate [96].